[Burden of irritable bowel syndrome in Korea]

Choi MG, Jung HK, Jang BH, Kim Y, Nam MH, Park SY, Park J, Park HJ, Lee PL, Lee JS, Lee KJ
Record ID 32014000424
Korean
Authors' recomendations: During a single year of 2008, the prevalence of IBS was 5.1% in males and 6.9% in females, yielding a female/male ratio of 1.44. According to the survey, the estimation of patients' quality of life by using the EQ-5D tool resulted in a score of 0.889 that was lower than the score (EQ-5D index) of 0.933 that was obtained by the general population in Korea. The total expenditure in 2008 for healthcare services and pharmacy services related to IBS, as estimated from the claims data from the HIRA, was approximately 349.9 billion won. The other costs were estimated to be transportation costs (90.3 billion won), direct costs (440.2 billion won), and loss of productivity (145.2 billion won). Thus, the total burden of irritable bowel syndrome was estimated to be 585.4 billion won. The ratio of medical costs was the highest at 60.0%, followed by transportation costs at 15.4% and productivity loss costs at 24.8%. If other medical costs incurred by patients, such as over-the-counter drug costs and health food costs, are added to the aforementioned costs, the total amount is estimated to be 773.8 billion won.
Details
Project Status: Completed
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: South Korea
MeSH Terms
  • Humans
  • Irritable Bowel Syndrome
  • Cost of Illness
  • Korea
Contact
Organisation Name: National Evidence-based healthcare Collaborating Agency
Contact Address: National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.
Contact Name: int@neca.re.kr
Contact Email: int@neca.re.kr
Copyright: National Evidence-based Healthcare Collaborating Agency (NECA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.